GlassScriptPhysician profile
Toby L Redden
NPI 1780091652
$1,370.17
in general payments reported to CMS, 2019-2025
18 companies · $634 in 2025
The $634 reported for 2025 was more than what 77% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $331 · 2022: $252 · 2023: $29.79 · 2024: $122 · 2025: $634.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $786.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $786.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $333.94 | 2021-2022 | |
| Abbott Laboratories | $249.01 | 2025 | Cardiomems, Ultreon |
| Verona Pharma, INC. | $121.47 | 2025 | Ohtuvayre |
| Mayne Pharma Commercial LLC | $86.15 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $85.13 | 2024-2025 | Farxiga, Lokelma |
| Merck Sharp & Dohme LLC | $68.01 | 2021-2025 | Verquvo |
| E.R. Squibb & Sons, L.L.C. | $61.74 | 2025 | Camzyos, Eliquis |
| Kiniksa Pharmaceuticals International, Plc | $53.43 | 2024 | Arcalyst |
| Genentech USA, INC. | $51.87 | 2021-2022 | |
| Pfizer INC. | $50.27 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.17 | 2025 | Jardiance |
| Lilly USA, LLC | $45.77 | 2021-2023 | Jaypirca, Mounjaro |
| Dynavax Technologies Corporation | $39.00 | 2021 | |
| Medtronic, INC. | $19.50 | 2025 | Symplicity G3 |
| Boston Scientific Corporation | $17.98 | 2024 | Watchman Access System |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $15.87 | 2025 | |
| Ferring Pharmaceuticals INC. | $12.66 | 2022 | |
| Abbvie INC. | $12.20 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Toby Redden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.